Skip to main
GOVX

Geovax Labs (GOVX) Stock Forecast & Price Target

Geovax Labs (GOVX) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Geovax Labs is a clinical-stage biotechnology company with a positive outlook, as they have a strong pipeline including GEO-MVA, GEO-CM04S1, and Gedeptin for poxviruses and solid tumor cancers. Despite a recent reverse stock split, the potential of Gedeptin in combination with immune checkpoint inhibitors and the differentiated multi-antigen approach of GEO-CM04S1 position Geovax Labs for future value inflection points. However, there is a heightened probability of dilution risk as the company continues to fund clinical development and manufacturing readiness with a constrained balance sheet.

Bears say

Geovax Labs is facing a constrained near-term outlook due to limited catalysts and tightening capital resources, prompting a downgrade from Buy to Hold. Although the company has a potentially differentiated role in the market with its GEO-MVA vaccine candidate for mpox, smallpox, and other poxviruses, the realization of its value will not be seen until a planned Phase 3 immunobridging trial in 2026 and data in 2027. In addition, the company's previous COVID vaccine effort has not translated into sustainable commercial success. As a result, the financial analyst has a negative outlook on Geovax Labs' stock due to the elevated risk of execution and potential dilutive capital raises.

Geovax Labs (GOVX) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geovax Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geovax Labs (GOVX) Forecast

Analysts have given Geovax Labs (GOVX) a Hold based on their latest research and market trends.

According to 1 analysts, Geovax Labs (GOVX) has a Hold consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geovax Labs (GOVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.